Ignite Creation Date:
2024-05-05 @ 4:48 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00315731
Status:
COMPLETED
Last Update Posted:
2017-07-11
First Post:
2006-04-17
Brief Title:
A Study Of Pharmacokinetics Whole Body And Organ Dosimetry And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab BEXXAR For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkins Lymphoma
Sponsor:
Organization:
GlaxoSmithKline
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
15
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
Observational Models:
Time Perspective List:
Who Masked List: